STREAM trial - discontinuing statins in older adults without cardiovascular disease
- the STREAM trial was an international, open-label, randomized, controlled trial evaluating whether discontinuing statin therapy in older adults with multimorbidity but no known cardiovascular disease is noninferior to continuing therapy
- background: whether discontinuing statin therapy in older adults with at least two chronic conditions and no history of cardiovascular disease affects time to a first cardiovascular event or death had not been well characterized
Study Design and Population
- population: 1880 community-dwelling adults aged 70 years or older (mean age 77.5 years, 46.9% women) taking statins for primary prevention with at least two chronic conditions
- intervention: participants were randomly assigned in a 1:1 ratio to either discontinue (n=938) or continue (n=942) statin therapy and other lipid-lowering therapies
- primary outcome: a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or death from any cause, whichever occurred first
- noninferiority criteria: assessed on the basis of the between-group difference in restricted mean event-free survival time at 2 years, using a predefined noninferiority margin of −5.2 weeks
Key Findings and Results
- primary outcome noninferiority: the between-group difference in restricted mean event-free survival time at 2 years was −2.0 weeks (95% CI, −3.7 to −0.3; p<0.001 for noninferiority), satisfying the predefined noninferiority threshold
- event rates: over a median follow-up of 103 weeks (approximately 2 years), primary outcome events occurred in 119 participants (12.7%) in the discontinuation group compared to 87 participants (9.2%) in the continuation group
- safety and serious adverse events: at least one serious adverse event occurred in 43.0% of participants in the discontinuation group and in 39.8% of participants in the continuation group
Primary Care Takeaway
- among older adults (aged 70 years and older) with multimorbidity (at least two chronic conditions) receiving statins for primary prevention, discontinuing statins was noninferior to continuing treatment regarding 2-year major cardiovascular events or all-cause mortality
- provides supportive clinical evidence for shared decision-making, polypharmacy management, and rational deprescribing of primary prevention statins in older patients
Reference:
- Rodondi N, Haller ML, Bardoczi JB, Adam L, Blum MR, Gencer B, et al., for the STREAM Investigators. Discontinuing statins in older adults without cardiovascular disease. N Engl J Med. 2026;395:NEJMoa2606634.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.